Kodiak Sciences Inc
Company Profile
Business description
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Contact
1250 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
124
Stocks News & Analysis
stocks
Are ASX REITs the better way to own property?
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,272.00 | 10.00 | -0.11% |
| CAC 40 | 8,636.80 | 13.76 | -0.16% |
| DAX 40 | 26,440.31 | 140.57 | 0.53% |
| Dow JONES (US) | 53,732.41 | 107.58 | -0.20% |
| FTSE 100 | 10,750.11 | 22.56 | -0.21% |
| HKSE | 25,521.99 | 405.14 | 1.61% |
| NASDAQ | 26,729.16 | 73.86 | -0.28% |
| Nikkei 225 | 68,895.98 | 182.18 | 0.27% |
| NZX 50 Index | 13,782.81 | 71.57 | -0.52% |
| S&P 500 | 7,785.76 | 13.23 | -0.17% |
| S&P/ASX 200 | 9,068.30 | 11.00 | -0.12% |
| SSE Composite Index | 3,960.19 | 33.01 | 0.84% |